Logo

Ambit to Profile Additional Compounds for Bristol-Myers, GSK, Pfizer

Jan 17, 2005

NEW YORK, Jan. 17 (GenomeWeb News) - Ambit Biosciences will profile additional compounds for Bristol-Myers Squibb, GlaxoSmithKline, and Pfizer using its kinase and screening technologies, the San Diego-based company said today.

 

Ambit will use its kinase platform to profile the specificity of certain compounds from GSK and Bristol-Myers. The platform consists of more than 170 quantitative, high-throughput kinase assays.

 

The company will also try to identify and characterize the protein targets of certain Pfizer compounds using its reverse screening technology that covers a large fraction of all human proteins.

 

Ambit has had previous collaborations with all three drug makers.

Breaking News
The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.